Live
- Supreme Court Limits Definition of "Material Resources of the Community"
- MP CM approves reservation for women upto 35 pc
- JMM-Cong-RJD plotted to alter Jharkhand's demography via land jihad, love jihad: Yogi Adityanath
- Country’s first museum on women achievers to open in Delhi next year: L-G
- India's Wedding Season Set to Generate Rs 6 Lakh Crore in Business, Marking 41% Growth
- Kharge campaigns in Jharkhand, replies to BJP’s ‘batenge toh katenge’ slogan
- Addressing shortage of qualified professionals in Indian healthcare crucial: Report
- Career opportunities in sustainable farming
- India Game Developer Conference 2024 to be held from November 13-15
- Former Rajasthan Minister Mahesh Joshi And 22 Others Face Allegations In ₹1000-Crore Jal Jeevan Mission Scam
Hyderabad: Covaxin clinical trails for children underway
(Picture used for representational purpose only)
Clinical trails are underway for Covaxin for the children between two and 18 years of age by the Bharat Biotech. Also, a clinical trial to learn the safety and immunogenicity of a booster dose is also in process.
Clinical trails are underway for Covaxin for the children between two and 18 years of age by the Bharat Biotech. Also, a clinical trial to learn the safety and immunogenicity of a booster dose is also in process.
The company said that they are carrying out the experiments on the variants of virus and assess their suitability for follow-up booster doses.
Bharath Biotech developed Covaxin received Emergency Use Authorizations (EUA) in 16 countries including, Brazil, India, Philippines, Iran, Mexico, etc. The company is in talks with WHO to obtain Emergency Use Listing (EUL) for Covaxin. The product has been exported to several countries, with additional requests for supplies being received.
At present, there are four facilities of Bharat Biotech within India, and further expansion is in process by the end of 2021.
